In the News
ADA consensus report calls for MASLD, liver fibrosis screening in type 2 diabetes
A two-tier system for stratifying patients based on their risk of metabolic dysfunction-associated steatotic liver disease (MASLD) was recommended by the American Diabetes Association (ADA).
Renal outcomes better with finerenone plus empagliflozin in type 2 diabetes and CKD
Patients with type 2 diabetes and chronic kidney disease (CKD) had a greater reduction in urinary albumin-to-creatinine ratio if they took finerenone plus empagliflozin versus either drug alone, an industry trial found.
Diabetes progression linked with increased risk of kidney cancer
Kidney cancer risk was significantly higher in patients with prolonged duration of diabetes, those with diabetic retinopathy or nephropathy, and those with poor glycemic control, a cohort study in South Korea found.
MKSAP quiz: Recurrent hypoglycemia
This month's quiz asks readers to evaluate a 64-year-old man who has recurrent hypoglycemia that occurs three to four times per week. He takes metformin, semaglutide, glipizide, dapagliflozin, lisinopril, and atorvastatin.
Spotlight on GLP-1 RA risks in older patients
Recent articles analyzed the risks of migraines, age-related macular degeneration, and loss of skeletal muscle mass in patients taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs) after age 65 years.
In type 2 diabetes with CKD and additional CV risk factors, sotagliflozin reduced total MACE vs. placebo at a median 14 mo
A manufacturer trial found cardiovascular (CV) benefits to sotagliflozin for patients with diabetes and chronic kidney disease (CKD), but the study did not prove it should be used in place of just a sodium-glucose cotransporter-2 inhibitor, an ACP Journal Club commentary said.
Two case series address hyperglycemia-related problems
One series describes patients who received enfortumab vedotin and then had hyperglycemia or diabetic ketoacidosis, while the other reports on some patients belatedly diagnosed with latent autoimmune diabetes of adults.
ACP releases new online modules on continuous glucose monitoring
The two-part series offers practical insights for integrating continuous glucose monitoring into treatment plans for patients with type 2 diabetes.